Jonathan Barratt, PhD, FRCP - From Mechanisms to Action: Exploring the Therapeutic Potential of Complement Inhibition in IgA Nephropathy

What this episode covers

For the complete activity, including supporting material, please visit https://www.peervoice.com/TZX860. Presented by Jonathan Barratt, PhD, FRC. Learning Objectives: Describe the relationship between the multi-hit hypothesis and disease trajectory in patients with IgA nephropathy (IgAN); Summarise the role and therapeutic implications of complement pathway dysregulation in IgAN disease progression; Differentiate between emerging therapeutic targets under investigation in patients with IgAN; Interpret data from clinical trials examining emerging therapies, including complement inhibitors, in the context of emerging guidance and approaches to IgAN management.

Distinct summary based on available episode metadata or transcript content.